The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners.

Junshi hopes new scientist CEO can cure its woes

The biotech company has been dogged by multiple challenges recently, including declining revenue, ongoing losses and a recent rejection by one of its overseas partners Key Takeaways: Junshi has appointed…

Drug maker Junshi seeks Swiss cure for cash woes

The biotech aims to raise 3.4 billion yuan through Swiss GDRs in its second major fund-raising push in just over six months Key Takeaways: Junshi Biosciences reported dismal results in…